Satpal Khattar Stock Portfolio: Holdings and Sectors
Satpal Khattar’s Stock Portfolio: The Key Numbers
Satpal Khattar’s disclosed stock portfolio is worth Rs 177.54 crore across 6 stocks, based on the latest quarterly shareholding filings tracked by Trendlyne’s Superstar Portfolio database. The portfolio value has grown 10.69% over the past quarter, a steadier pace than several other portfolios in this dataset.
This article covers the sector breakdown, the top holdings, and what a heavily pharma weighted, 6 stock portfolio suggests about the investing approach behind it.
Where this kind of data comes from
Under SEBI rules, any individual who owns 1% or more of a listed Indian company’s shares must be named in that company’s shareholding pattern, which gets filed with the stock exchanges every quarter. This applies uniformly to every listed company, which is how platforms like Trendlyne build a consistent, exchange sourced view across many investors.
It is worth being clear about what this data does and does not show. It only reflects stakes above the 1% threshold in individual companies. It does not capture mutual fund holdings, smaller stock positions, or other assets, so a 6 stock disclosed portfolio may only be one visible piece of a much larger overall investment picture.
Sector Allocation: Pharma Dominates
This portfolio is unusually concentrated in a single sector:
| Sector | Weight |
|---|---|
| Pharmaceuticals & Biotechnology | 83.55% |
| Cement and Construction | 11.64% |
| Food, Beverages & Tobacco | 3.74% |
Pharmaceuticals & Biotechnology alone accounts for more than four out of every five rupees in this portfolio. That is one of the more extreme single sector weightings among the portfolios tracked in this dataset, and it means the fortunes of this portfolio are closely tied to how the pharma sector performs as a whole.
What this level of concentration signals
A portfolio this heavily weighted toward one sector usually reflects deep familiarity or strong conviction in that specific industry, rather than an attempt to build a balanced, all weather portfolio. Investors with this kind of tilt are often making a long term, structural bet on the sector’s growth rather than trading around short term news.
The tradeoff is straightforward. When the pharma sector does well, whether due to strong export demand, new drug approvals, or favorable regulatory changes, a portfolio this concentrated benefits disproportionately. When the sector faces headwinds, like pricing pressure or regulatory scrutiny in key export markets, the impact on total portfolio value is also amplified.
Top Holdings in the Portfolio
Three stocks make up the visible core of this portfolio:
- Strides Pharma Science, valued at Rs 148.33 crore, by far the dominant holding
- Gayatri Projects, valued at Rs 14.78 crore
- Nath Bio-Genes India, valued at Rs 6.65 crore
Strides Pharma Science alone accounts for roughly 84% of the total disclosed portfolio value, making it the clear anchor position. Strides is a known name in the pharmaceutical manufacturing space, with a business built around generic drug formulations, a segment that depends heavily on regulatory approvals, export markets, and manufacturing quality standards.
Gayatri Projects sits in the Cement and Construction sector, tied to infrastructure activity, government spending on roads and construction, and cement demand cycles. Nath Bio-Genes India operates in the agricultural biotechnology and seed space, a smaller but distinct part of the broader life sciences and biotech theme running through this portfolio.
No Recent Trading Activity Disclosed
There is no disclosed buying or selling activity for this investor in the most recent quarter. All three visible holdings appear to have remained steady in terms of stake size.
A quiet quarter with no reported changes often points to a long term, buy and hold approach rather than active trading. It is also possible that any activity below the 1% disclosure threshold simply would not appear in this data even if it occurred.
Why This Concentration Deserves Extra Caution
An 83.55% weighting in a single sector is worth flagging clearly for anyone using this data as a research reference. Sector concentration at this level means:
- Regulatory changes affecting the pharmaceutical industry, whether in India or in key export markets like the United States, can move this portfolio’s value meaningfully.
- Company specific news at Strides Pharma Science, given its outsized weight, will likely dominate overall portfolio performance more than news at the other two holdings combined.
- Diversification benefits that usually cushion a portfolio during a sector downturn are largely absent here.
None of this means the strategy is wrong. Concentrated, sector focused investing is a legitimate approach used by many experienced investors who understand a specific industry well. It simply carries a different risk profile than a spread out portfolio, and readers should weigh that before drawing any conclusions from the disclosed numbers alone.
Reading This Data With the Right Context
A few caveats apply before using this information for any decision:
- Entry price and timing are unknown. The 10.69% quarterly gain reflects portfolio value movement, not the return earned from each stock’s original purchase price.
- This is a quarterly snapshot. The picture here may already be outdated by the time it becomes public.
- Position sizing matters as much as stock choice. With one stock making up 84% of value, this portfolio behaves almost like a single stock bet with two smaller satellite positions.
- Use this as a research starting point. Public shareholding data is useful for understanding who holds meaningful stakes in a company, not as a signal to copy trades.
Summary
Satpal Khattar’s disclosed portfolio is worth Rs 177.54 crore across 6 stocks, up 10.69% this quarter. Pharmaceuticals & Biotechnology dominates at 83.55% of total value, anchored almost entirely by Strides Pharma Science at Rs 148.33 crore, with smaller positions in Gayatri Projects and Nath Bio-Genes India. No buying or selling activity was disclosed this quarter. This is one of the most concentrated portfolios in the dataset, and readers should treat it as a case study in sector conviction rather than a diversified model to follow.
FAQ
How much is Satpal Khattar’s disclosed stock portfolio worth?
It stands at Rs 177.54 crore across 6 stocks as per the latest quarterly filing, up 10.69% from the previous quarter.
What is the largest stock in this portfolio?
Strides Pharma Science is the dominant holding at Rs 148.33 crore, making up about 84% of the entire disclosed portfolio.
Why is Pharmaceuticals & Biotechnology such a large part of this portfolio?
The anchor holding, Strides Pharma Science, is a pharmaceutical manufacturer, which explains why the sector accounts for 83.55% of total portfolio value.
Were there any recent buys or sells in this portfolio?
No trading activity was disclosed in the latest quarterly filing, suggesting the existing positions were held steady.
Is a portfolio this concentrated in one sector considered risky?
Yes, relative to a diversified portfolio. An 83.55% weighting in one sector means sector specific news has an outsized effect on total portfolio value compared to a more spread out approach.
Key Takeaways
- Satpal Khattar’s disclosed portfolio is worth Rs 177.54 crore across 6 stocks, up 10.69% this quarter.
- Pharmaceuticals & Biotechnology makes up 83.55% of the portfolio, one of the highest single sector weightings in this dataset.
- Strides Pharma Science is the anchor holding at Rs 148.33 crore, or roughly 84% of total value.
- Gayatri Projects and Nath Bio-Genes India are the two smaller holdings, in Cement and Construction and agri biotech respectively.
- No buying or selling activity was disclosed this quarter.
- This level of sector concentration amplifies both potential gains and potential losses tied to the pharma industry.
- Treat this data as a research reference on sector conviction, not a signal to copy trades.
